<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">72626</article-id><article-id pub-id-type="doi">10.7554/eLife.72626</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Patient-specific Boolean models of signalling networks guide personalised treatments</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-247852"><name><surname>Montagud</surname><given-names>Arnau</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7696-1241</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-247831"><name><surname>Béal</surname><given-names>Jonas</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-247832"><name><surname>Tobalina</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-247833"><name><surname>Traynard</surname><given-names>Pauline</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-247834"><name><surname>Subramanian</surname><given-names>Vigneshwari</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-247835"><name><surname>Szalai</surname><given-names>Bence</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-247836"><name><surname>Alföldi</surname><given-names>Róbert</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-247837"><name><surname>Puskás</surname><given-names>László</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-7284"><name><surname>Valencia</surname><given-names>Alfonso</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8937-6789</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-34780"><name><surname>Barillot</surname><given-names>Emmanuel</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-156760"><name><surname>Saez-Rodriguez</surname><given-names>Julio</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8552-8976</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" corresp="yes" id="author-148074"><name><surname>Calzone</surname><given-names>Laurence</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7835-1148</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution>Barcelona Supercomputing Center (BSC)</institution>, <addr-line><named-content content-type="city">Barcelona</named-content></addr-line>, <country>Spain</country></aff><aff id="aff2"><institution>Institut Curie, PSL Research University</institution>, <addr-line><named-content content-type="city">Paris</named-content></addr-line>, <country>France</country></aff><aff id="aff3"><institution content-type="dept">Faculty of Medicine, Joint Research Centre for Computational Biomedicine (JRC-COMBINE)</institution>, <institution>RWTH Aachen University</institution>, <addr-line><named-content content-type="city">Aachen</named-content></addr-line>, <country>Germany</country></aff><aff id="aff4"><institution content-type="dept">Department of Physiology</institution>, <institution>Semmelweis University</institution>, <addr-line><named-content content-type="city">Budapest</named-content></addr-line>, <country>Hungary</country></aff><aff id="aff5"><institution>Astridbio Technologies Ltd</institution>, <addr-line><named-content content-type="city">Szeged</named-content></addr-line>, <country>Hungary</country></aff><aff id="aff6"><institution content-type="dept">Institute of Computational Biomedicine</institution>, <institution>Heidelberg University</institution>, <addr-line><named-content content-type="city">Heidelberg</named-content></addr-line>, <country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-195903"><name><surname>Flegg</surname><given-names>Jennifer</given-names></name><role>Reviewing editor</role><aff><institution>The University of Melbourne</institution>, <country>Australia</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>arnau.montagud@bsc.es</email> (AM);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>Laurence.Calzone@curie.fr</email> (LC);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>15</day><month>02</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e72626</elocation-id><history><date date-type="received"><day>30</day><month>07</month><year>2021</year></date><date date-type="accepted"><day>27</day><month>01</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Montagud et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Montagud et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-72626-v1.pdf"/><abstract><p>Prostate cancer is the second most occurring cancer in men worldwide. To better understand the mechanisms of tumorigenesis and possible treatment responses, we developed a mathematical model of prostate cancer which considers the major signalling pathways known to be deregulated. We personalised this Boolean model to molecular data to reflect the heterogeneity and specific response to perturbations of cancer patients. 488 prostate samples were used to build patient-specific models and compared to available clinical data. Additionally, eight prostate cell-line-specific models were built to validate our approach with dose-response data of several drugs. The effects of single and combined drugs were tested in these models under different growth conditions. We identified 15 actionable points of interventions in one cell-line-specific model whose inactivation hinders tumorigenesis. To validate these results, we tested nine small molecule inhibitors of five of those putative targets and found a dose-dependent effect on four of them, notably those targeting HSP90 and PI3K. These results highlight the predictive power of our personalised Boolean models and illustrate how they can be used for precision oncology.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000780</institution-id><institution>European Commission</institution></institution-wrap></funding-source><award-id>H2020-PHC-668858</award-id><principal-award-recipient><name><surname>Montagud</surname><given-names>Arnau</given-names></name><name><surname>Béal</surname><given-names>Jonas</given-names></name><name><surname>Tobalina</surname><given-names>Luis</given-names></name><name><surname>Traynard</surname><given-names>Pauline</given-names></name><name><surname>Subramanian</surname><given-names>Vigneshwari</given-names></name><name><surname>Szalai</surname><given-names>Bence</given-names></name><name><surname>Alföldi</surname><given-names>Róbert</given-names></name><name><surname>Puskás</surname><given-names>László</given-names></name><name><surname>Barillot</surname><given-names>Emmanuel</given-names></name><name><surname>Saez-Rodriguez</surname><given-names>Julio</given-names></name><name><surname>Calzone</surname><given-names>Laurence</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000780</institution-id><institution>European Commission</institution></institution-wrap></funding-source><award-id>H2020-ICT-825070</award-id><principal-award-recipient><name><surname>Montagud</surname><given-names>Arnau</given-names></name><name><surname>Valencia</surname><given-names>Alfonso</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000780</institution-id><institution>European Commission</institution></institution-wrap></funding-source><award-id>H2020-ICT-951773</award-id><principal-award-recipient><name><surname>Montagud</surname><given-names>Arnau</given-names></name><name><surname>Valencia</surname><given-names>Alfonso</given-names></name><name><surname>Barillot</surname><given-names>Emmanuel</given-names></name><name><surname>Saez-Rodriguez</surname><given-names>Julio</given-names></name><name><surname>Calzone</surname><given-names>Laurence</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Luis Tobalina, is a full-time employee and shareholder of AstraZeneca..</p></fn><fn fn-type="conflict" id="conf3"><p>Vigneshwari Subramanian, is a full-time employee of AstraZeneca..</p></fn><fn fn-type="conflict" id="conf4"><p>Róbert Alföldi, is CEO of Astridbio Technologies Ltd..</p></fn><fn fn-type="conflict" id="conf5"><p>László Puskás, is a scientific advisor of Astridbio Technologies Ltd..</p></fn><fn fn-type="conflict" id="conf6"><p>Alfonso Valencia, Reviewing editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf7"><p>Julio Saez-Rodriguez, receives funding from GSK and Sanofi and consultant fees from Travere Therapeutics. The other authors declare no conflicts of interest.-.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Code (and processed data) to reproduce the analyses can be found in a dedicated GitHub (https://github.com/ArnauMontagud/PROFILE_v2), some of the code used in the work can be found in other GitHub repositories (https://github.com/sysbio-curie/PROFILE; https://github.com/sysbio-curie/Logical_modelling_pipeline).The model built can be accessed on the SuppFile1 and on BioModels and GINsim model repositories (https://www.ebi.ac.uk/biomodels/MODEL2106070001; http://ginsim.org/model/signalling-prostate-cancer).</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Hoadley et al (DOI:https://doi.org/10.1016/j.cell.2018.03.022)</collab></person-group><year iso-8601-date="2018">2018</year><source>Prostate Adenocarcinoma (TCGA, PanCancer Atlas)</source><ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018">https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018</ext-link><comment>cBioPortal</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Iorio et al (DOI:https://doi.org/10.1016/j.cell.2016.06.017)</collab></person-group><year iso-8601-date="2016">2016</year><source>GDSC 1 and 2</source><ext-link ext-link-type="uri" xlink:href="https://www.cancerrxgene.org/downloads/bulk_download">https://www.cancerrxgene.org/downloads/bulk_download</ext-link><comment>Genomics of Drug Sensitivity in Cancer</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-72626-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>